WFRF:(Pordy Robert)
Search: WFRF:(Pordy Robert) > Alirocumab and Card...
- 2 of 5
- Previous record
- Next record
- To hitlist
Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction : Prespecified Subanalysis From ODYSSEY OUTCOMES
- Chiang, Chern-En (author)
- Schwartz, Gregory G (author)
- Elbez, Yedid (author)
- show more...
- Szarek, Michael (author)
- Bhatt, Deepak L (author)
- Bittner, Vera A (author)
- Diaz, Rafael (author)
- Erglis, Andrejs (author)
- Goodman, Shaun G (author)
- Jukema, J Wouter (author)
- Liberopoulos, Evangelos (author)
- Loy, Megan (author)
- Pordy, Robert (author)
- White, Harvey D (author)
- Simon, Tabassome (author)
- Steg, Philippe Gabriel (author)
- show less...
- (creator_code:org_t)
- Elsevier, 2022
- 2022
- English.
- In: Canadian Journal of Cardiology. - : Elsevier. - 0828-282X .- 1916-7075. ; 38:10, s. 1542-1549
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- BACKGROUND: After acute coronary syndrome (ACS), patients with a previous myocardial infarction (MI) may be at particularly high risk for major adverse cardiovascular events (MACE) and death. We studied the effects of the PCSK9 inhibitor alirocumab in patients with recent ACS according to previous history of MI.METHODS: The ODYSSEY OUTCOMES trial compared alirocumab with placebo, beginning 1 to 12 months after ACS with median 2.8-year follow-up. The primary MACE outcome comprised death from coronary heart disease, nonfatal MI, fatal or nonfatal ischemic stroke, and hospitalization for unstable angina. Of 18,924 patients, 3633 (19.2%) had previous MI.RESULTS: Patients with previous MI were older, more likely male, with more cardiovascular risk factors and previous events. With placebo, 4-year risks of MACE and death were higher among those with vs without previous MI (20.5% vs 8.9%, P < 0.001; 7.4% vs 3.4%, P < 0.001, respectively). Alirocumab reduced the risk of events regardless of the presence or absence of a history of MI (MACE, adjusted hazard ratio [aHR] 0.90, 95% confidence interval [CI], 0.78-1.05 vs 0.82, 0.73-0.92; Pinteraction = 0.34; death, aHR 0.84; 95% CI, 0.64-1.08 vs 0.87, 0.72-1.05; Pinteraction = 0.81). Estimated absolute risk reductions with alirocumab were numerically greater with vs without previous MI (MACE, 1.91% vs 1.42%; death, 1.35% vs 0.41%).CONCLUSIONS: A previous history of MI places patients with recent ACS at high risk for recurrent MACE and death. Alirocumab reduced the relative risks of these events consistently in patients with or without previous MI but with numerically greater absolute benefit in the former subgroup. (ODYSSEY OUTCOMES: NCT01663402).
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Canadian Journal of Cardiology (Search for host publication in LIBRIS)
To the university's database
- 2 of 5
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Chiang, Chern-En
- Schwartz, Gregor ...
- Elbez, Yedid
- Szarek, Michael
- Bhatt, Deepak L
- Bittner, Vera A
- show more...
- Diaz, Rafael
- Erglis, Andrejs
- Goodman, Shaun G
- Hagström, Emil
- Jukema, J Wouter
- Liberopoulos, Ev ...
- Loy, Megan
- Pordy, Robert
- White, Harvey D
- Simon, Tabassome
- Steg, Philippe G ...
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cardiac and Card ...
- Articles in the publication
- Canadian Journal ...
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
